Market Cap (In USD)
1.53 Billion
Revenue (In USD)
781.42 Million
Net Income (In USD)
-83.91 Million
Avg. Volume
87.95 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.85-12.0
- PE
- -
- EPS
- -
- Beta Value
- 0.984
- ISIN
- US30050E1055
- CUSIP
- 30050E105
- CIK
- 1412558
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Dr. Christian Wojczewski
- Employee Count
- -
- Website
- https://www.evotec.com
- Ipo Date
- 2004-02-05
- Details
- Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
More Stocks
-
ORIENTBELLOrient Bell Limited
ORIENTBELL
-
WDHWaterdrop Inc.
WDH
-
060250NHN KCP Corp.
060250
-
BDWBF
-
9991Gecoss Corporation
9991
-
YNNHF
-
JWNGJaywing plc
JWNG
-
VRX